Stocks · News reference
Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.494
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 8:58 PM
- Checked
- Aug 14, 2026, 8:58 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
HIVE Digital Technologies Ltd (NASDAQ: HIVE) rose in pre-market trading due to its subsidiary's new agreement. Other gainers include IP Strategy Holdings, INVO Fertility, My Size, Trugolf Holdings, Expion360, Skye Bioscience, Julong Holding, FIEE Inc, and Keel Infrastructure. Losers include Generation Income Properties, Barfresh Food Group, iTonic Holdings, Akanda Corp, and Reservoir Media.
Read original at benzinga8-K filing — CITIUS ONCOLOGY, INC. (CTOR)
Filed: 2026-08-14 AccNo: 0001213900-26-090182 Size: 332 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar